Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1986 3
1989 1
1990 5
1991 5
1992 5
1993 6
1994 2
1995 8
1996 3
1997 1
1998 2
1999 4
2000 2
2001 11
2002 6
2003 4
2004 5
2005 5
2006 5
2007 6
2008 4
2009 9
2010 12
2011 11
2012 9
2013 9
2014 8
2015 8
2016 6
2017 6
2018 11
2019 9
2020 8
2021 9
2022 6
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Natural Killer Cell Lymphoblastic Leukemia/Lymphoma"
Page 1
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Liu E, et al. N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607. N Engl J Med. 2020. PMID: 32023374 Free PMC article. Clinical Trial.
Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations. METHODS: In this phase 1 and 2 trial, we administered HLA-mismatched anti-CD19 CAR-NK cells derived from cord blood t …
Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limi …
IL-15 in the Combination Immunotherapy of Cancer.
Waldmann TA, Dubois S, Miljkovic MD, Conlon KC. Waldmann TA, et al. Front Immunol. 2020 May 19;11:868. doi: 10.3389/fimmu.2020.00868. eCollection 2020. Front Immunol. 2020. PMID: 32508818 Free PMC article. Review.
To translate IL-15-mediated increases in NK cells, we investigated combination therapy of IL-15 with anticancer monoclonal antibodies including rituximab in mouse models of EL-4 lymphoma transfected with human CD20 and with alemtuzumab (CAMPATH-1H) in a xenograft mo …
To translate IL-15-mediated increases in NK cells, we investigated combination therapy of IL-15 with anticancer monoclonal antibodies …
CD38 antibodies in multiple myeloma: back to the future.
van de Donk NWCJ, Richardson PG, Malavasi F. van de Donk NWCJ, et al. Blood. 2018 Jan 4;131(1):13-29. doi: 10.1182/blood-2017-06-740944. Epub 2017 Nov 8. Blood. 2018. PMID: 29118010 Free article. Review.
CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic origin. ...Furthermore, CD38 antibodies are currently also under investigation in …
CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively low levels on normal lymphoid and mye …
Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia.
Tan Y, Shan L, Zhao L, Deng B, Ling Z, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Tian Z, Zhang Y, Zhang J, Chang AH, Feng X, Pan J. Tan Y, et al. J Hematol Oncol. 2023 Apr 5;16(1):34. doi: 10.1186/s13045-023-01427-3. J Hematol Oncol. 2023. PMID: 37020231 Free PMC article.
BACKGROUND: Donor-derived CD7-directed chimeric antigen receptor (CAR) T cells showed feasibility and early efficacy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia (r/r T-ALL), in a previous phase I trial report, at …
BACKGROUND: Donor-derived CD7-directed chimeric antigen receptor (CAR) T cells showed feasibility and early efficacy in patients with …
Natural killer cells.
Kay NE. Kay NE. Crit Rev Clin Lab Sci. 1986;22(4):343-59. doi: 10.3109/10408368509165790. Crit Rev Clin Lab Sci. 1986. PMID: 2419034 Review.
It is proposed that this article will encompass a review of primarily the human natural killer cell. The following parameters of the human natural killer (NK) cell will be reviewed: its ontogeny; surface membrane characteristics including …
It is proposed that this article will encompass a review of primarily the human natural killer cell. The following para …
Central Nervous System Involvement of Natural Killer and T Cell Neoplasms.
Aaroe AE, Nevel KS. Aaroe AE, et al. Curr Oncol Rep. 2019 Mar 27;21(5):40. doi: 10.1007/s11912-019-0794-2. Curr Oncol Rep. 2019. PMID: 30919085 Review.
PURPOSE OF REVIEW: Peripheral natural killer (NK) and T cell neoplasms comprise approximately 10-15% of non-Hodgkin lymphomas. There are 27 different subtypes of peripheral NK and T cell neoplasms, each of which is relatively uncommon. Treatment …
PURPOSE OF REVIEW: Peripheral natural killer (NK) and T cell neoplasms comprise approximately 10-15% of non-Hodgkin …
Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
Jiang J, Chen J, Liao C, Duan Y, Wang Y, Shang K, Huang Y, Tang Y, Gao X, Gu Y, Sun J. Jiang J, et al. Leukemia. 2023 Aug;37(8):1660-1670. doi: 10.1038/s41375-023-01948-3. Epub 2023 Jun 30. Leukemia. 2023. PMID: 37391486
CAR-T therapies to treat T-cell malignancies face unique hurdles. Normal and malignant T cells usually express the same target for CAR, leading to fratricide. ...Moreover, EF1alpha-driven CAR expressed at the CD7 locus enhances tumor rejection in a mouse xenograft m …
CAR-T therapies to treat T-cell malignancies face unique hurdles. Normal and malignant T cells usually express the same target …
Lymphoma study group of JCOG.
Tsukasaki K, Tobinai K, Hotta T, Shimoyama M. Tsukasaki K, et al. Jpn J Clin Oncol. 2012 Feb;42(2):85-95. doi: 10.1093/jjco/hyr168. Epub 2011 Dec 6. Jpn J Clin Oncol. 2012. PMID: 22147803 Review.
JCOG-LSG has focused on combined modalities, dose intensification and the incorporation of new agents for major disease entities of lymphoid malignancies. More than 30 trials including 10 randomized trials have been conducted for aggressive non-Hodgkin's lymphoma …
JCOG-LSG has focused on combined modalities, dose intensification and the incorporation of new agents for major disease entities of lymph …
KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target.
Cheminant M, Lhermitte L, Bruneau J, Sicard H, Bonnafous C, Touzart A, Bourbon E, Ortonne N, Genestier L, Gaulard P, Palmic P, Suarez F, Frenzel L, Naveau L, Bazarbachi A, Dussiot M, Waast L, Avettand-Fenoel V, Brouzes C, Pique C, Lepelletier Y, Asnafi V, Marçais A, Hermine O. Cheminant M, et al. Blood. 2022 Sep 29;140(13):1522-1532. doi: 10.1182/blood.2022016765. Blood. 2022. PMID: 35687761 Free article. Clinical Trial.
Adult T-cell leukemia (ATL) is a lymphoid neoplasm caused by human T-cell leukemia virus type 1 (HTLV-1), which encodes the transcriptional activator Tax, which participates in the immortalization of infected T cells. ATL is classified in …
Adult T-cell leukemia (ATL) is a lymphoid neoplasm caused by human T-cell leukemia virus type 1 (HTLV-1), …
Epstein-Barr virus-infected natural killer cell leukemia.
Akashi K, Mizuno S. Akashi K, et al. Leuk Lymphoma. 2000 Dec;40(1-2):57-66. doi: 10.3109/10428190009054881. Leuk Lymphoma. 2000. PMID: 11426629 Review.
Natural killer cell leukemia (NK leukemia) is an aggressive form of lymphoproliferative disease of granular lymphocytes, and frequently complicates fulminant hemophagocytic lymphohistiocytosis. ...The NK leukemia cells lack endogen …
Natural killer cell leukemia (NK leukemia) is an aggressive form of lymphoproliferative disease of granul …
198 results